Neuberger Berman Group LLC Editas Medicine, Inc. Transaction History

Neuberger Berman Group LLC

  • $123 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Nov 14, 2024
BUY
$7.03 - $11.07 $1.93 Million - $3.05 Million
275,069 New
275,069 $2.04 Million
Q1 2024

May 13, 2024
BUY
$7.03 - $11.07 $1.93 Million - $3.05 Million
275,069 New
275,069 $2.04 Million
Q1 2021

May 13, 2021
SELL
$39.71 - $90.58 $1.14 Million - $2.59 Million
-28,594 Closed
0 $0
Q4 2020

Feb 10, 2021
BUY
$27.07 - $84.35 $774,039 - $2.41 Million
28,594 New
28,594 $2.02 Million

Others Institutions Holding EDIT

# of Institutions
248
Shares Held
57M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email